Liminatus Pharma, Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 |
|---|---|---|---|
| Income Statement | |||
| Operating income | -$3.0 | -$3.3 | — |
| Net income | -$10.2 | -$3.5 | — |
| Cash Flow Statement | |||
| Free cash flow | -$10.0 | — | — |
Shares outstanding 44.9M · Free float 12.7%
Annual filing data through FY ended December 31, 2025; float as of July 16, 2026.